orelabrutinib
Asset
CNS-penetrable Bruton's tyrosine kinase (BTK) inhibitor reducing B cell and microglia-mediated inflammation.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Inflammation
- 2
- Indications
- 2
- Trials
- 1
- Developer
Indications
2Multiple sclerosis (ms) primary progressive
Phase 3, Recruiting, NCT07067463, clinicaltrials.gov, 7 Oct 2026
Secondary progressive multiple sclerosis
Phase 3, Recruiting, NCT07299019, clinicaltrials.gov, 8 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials2
- Evidence for its targets2
- Competitors6
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 8 Oct 2026, 2 sources